THYROID DISORDERS IN HIV PATIENTS: A SINGLE CENTRE CROSS-SECTIONAL STUDY

Devinder Kumar Vohra¹, Gaurav Garg², Yogita Singh³, Snehlata Verma⁴, Rahul Goel⁵, Alka Srivastava⁶

¹Associate Professor, Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh.
²Associate Professor, Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh.
³Associate Professor, Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh.
⁴Assistant Professor, Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh.
⁵Junior Resident, Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh.
⁶Lecturer, Department of Physiology, LLRM Medical College, Meerut, Uttar Pradesh.

ABSTRACT

BACKGROUND
There is report of increasing prevalence of thyroid disorders in HIV positive patients. Currently, there is insufficient data to recommend routine screening for thyroid disorders in asymptomatic HIV patients; hence, this study was undertaken to resolve these issues.

MATERIALS AND METHODS
This is a comparative descriptive study of 150 seropositive HIV patients, which was taken for convenience conducted at LLRM Medical College and SVBP Hospital, Meerut, U.P.

RESULTS
Overt hypothyroidism was found in 3.33% patients, subclinical hypothyroidism was found in 9.33% patients, isolated low FT4 was found in 2.66% patients, while sick euthyroid syndrome was found in 26% patients. None of the patients was found to be having hyperthyroidism. As the disease progressed FT4 and FT3 levels decreased, while TSH level increased. A direct positive correlation between FT4, FT3 and CD4 count was established, while a negative correlation between S. TSH and CD4 count was found. Mean FT3 and FT4 levels were lower in patients on HAART, while mean TSH level was higher in patients on HAART.

CONCLUSION
Thyroid dysfunction in HIV patients was largely asymptomatic. There was a direct correlation between WHO clinical stage and FT3 and FT4 levels. TSH level increased as CD4 count decreased. Patients on HAART had a higher prevalence of subclinical hypothyroidism.

KEYWORDS
HIV-, Human Immunodeficiency Virus, TSH, HAART, FT3.


BACKGROUND
The prevalence of human immunodeficiency virus (HIV) infection in India is estimated to be 2.4 million. HIV infection can lead to involvement of various organs and systems including endocrine glands. Alteration in endocrine functions may be due to the possible relationship between the immune and endocrine systems, direct involvement of the glands by the HIV itself, opportunistic infections or malignancies, highly active anti-retroviral therapy (HAART) and drugs used to treat the opportunistic infections. Although, the prevalence of overt thyroid disease does not appear to be significantly increased as compared to general population, subtle thyroid dysfunction is common, believed to occur in as many as 35% of all HIV infected individuals. Earlier studies have evaluated the possible relationship of thyroid dysfunction in HIV. In India, there are only very few reports on thyroid dysfunction in HIV patients.

The prevalence and relationship of thyroid autoantibodies in various stages of disease and therapy has not been studied. There was no report of hyperthyroidism in these publications, despite reports of resurgence of autoimmunity leading on to Graves’ disease in immune reconstitution inflammatory syndrome. So further studies are required to confirm this. Hence, the present study is designed to answer the above uncertainties. This study also assesses whether universal screening of thyroid function could be enforced in HIV patients.

Aims and Objectives
1. To study the thyroid dysfunction, both clinical and biochemical in HIV positive patients.
2. To correlate the thyroid function changes in these patients with their CD4 cell count, WHO clinical stage and duration of HAART.

MATERIALS AND METHODS
This is a comparative descriptive study of 150 seropositive HIV patients, which was taken for convenience conducted at LLRM Medical College and SVBP Hospital, Meerut, U.P. Duration of the study was one year from Nov. 2016 to October 2017. The Institutional Ethics Committee approval was taken. Informed consent was obtained from all patients and patient confidentiality was maintained.
Inclusion Criterion
1. Subjects with HIV serology positive by ELISA test.
2. Age greater than or equal to 18 years.
3. Subjects consenting to take part in the study.

Exclusion Criteria
1. Known cases of thyroid disorder.
2. Patients on drugs altering thyroid hormones metabolism and stavudine-based antiretroviral drugs.
3. Diabetic patients.
4. Abnormal liver function tests with SGOT/SGPT levels greater than 3 times normal range and abnormal renal function tests with serum creatinine greater than 1.6 mg%.

Based on Inclusion and Exclusion Criteria, Patients were Grouped into:
- **Group A**: Treatment naive. (n= 50)
- **Group B**: Taking HAART for less than a year (n= 50)
- **Group C**: Taking HAART for a year or more (n= 50)

All patients were evaluated with history taking, physical examination and biochemical investigations. CD4 count was done in all the patients and patients were categorised as per WHO clinical stage. FT3, FT4 and TSH were measured at the endocrinology laboratory of our hospital by chemiluminescent immunoassay. The coefficient of variance for FT3 was 1.71 - 3.71 pg/dL, for FT4 was 0.70 - 1.48 ng/dL and that for TSH was 0.3500 - 4.9400 µIU/mL.

Statistical Analysis
Data analysis was done with the help of SPSS software version 15 and Sigma plot version 11. Quantitative data is presented with the help of mean and standard deviation, comparison between study groups was done with the help of unpaired T-test or Mann-Whitney test as per the result of normality test. Pearson correlation coefficient test was used to describe correlation between continuous variables like thyroid function test and CD4 count. Qualitative data is presented with the help of frequency and percentage table, association among study groups is assessed with the help of chi-square test. P-value < 0.05 is taken as significant.

RESULTS
Majority patients in the study were males (74%) with age group 21 - 40 years (77%), most of the patients were in the weight group 40 - 60 kg (97%), only 1 patient enrolled in the study had weight > 60 kg while 3 patients had weight < 40 kg. Number of patients in each group enrolled was 50.

Out of 150 patients 74 (49%) had HIV duration less than 1 year, while 76 (51%) had HIV duration more than 1 year. 84 patients (56%) had CD4 count < 350/mm³, while 38 patients (25%) had CD4 count between 351 - 700/mm³ and 28 patients (19%) had CD4 count > 700/mm³.

Most of the HIV patients who had thyroid dysfunction have CD4 count < 350 [Table 2] and thyroid function abnormalities were more common in patients on ART when compared with patients not on ART [Table 3].

<table>
<thead>
<tr>
<th>Thyroid Disorder</th>
<th>No. of Patients</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overt hypothyroidism</td>
<td>5 (3.33%)</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Subclinical hypothyroidism</td>
<td>14 (9.33%)</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Isolated low F-T4</td>
<td>4 (2.66%)</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Sick euthyroidism (Isoalted low FT3)</td>
<td>39 (26%)</td>
<td>29</td>
<td>10</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Euthyroidism</td>
<td>88 (58.66%)</td>
<td>69</td>
<td>19</td>
</tr>
<tr>
<td>Total</td>
<td>n=150</td>
<td>111 (74%)</td>
<td>39 (26%)</td>
</tr>
</tbody>
</table>

*Table 1. Prevalence of Thyroid Dysfunction in the Study*

<table>
<thead>
<tr>
<th>CD4 Count (mm³)</th>
<th>Overt Hypothyroidism</th>
<th>Subclinical Hypothyroidism</th>
<th>Isolated Low FT4</th>
<th>Sick Euthyroidism (Isolated Low FT3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;350</td>
<td>4(80%)</td>
<td>12(86%)</td>
<td>1(25%)</td>
<td>37(95%)</td>
</tr>
<tr>
<td>351-700</td>
<td>1(20%)</td>
<td>2(14%)</td>
<td>3(75%)</td>
<td>2(5%)</td>
</tr>
<tr>
<td>&gt;700</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>n=5</td>
<td>n=14</td>
<td>n=4</td>
<td>n=39</td>
</tr>
</tbody>
</table>

*Table 2. Distribution of Thyroid Dysfunction according to CD4 Count*

<table>
<thead>
<tr>
<th>ART Group</th>
<th>Overt Hypothyroidism</th>
<th>Subclinical Hypothyroidism</th>
<th>Isolated Low FT4</th>
<th>Sick Euthyroidism (Isolated Low FT3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (n=50)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4 (10.25%)</td>
</tr>
<tr>
<td>B (n=50)</td>
<td>1 (20%)</td>
<td>5 (36%)</td>
<td>1 (25%)</td>
<td>17 (43%)</td>
</tr>
<tr>
<td>C (n=50)</td>
<td>4 (80%)</td>
<td>9 (64%)</td>
<td>3 (75%)</td>
<td>18 (46%)</td>
</tr>
<tr>
<td>Total</td>
<td>n=5</td>
<td>n=14</td>
<td>n=4</td>
<td>n=39</td>
</tr>
</tbody>
</table>

*Table 3. Distribution of Thyroid Dysfunction according to ART Group*

<table>
<thead>
<tr>
<th>Thyroid Function Test (Mean ± SD)</th>
<th>Group A (n=50)</th>
<th>Group B (n=50)</th>
<th>Unpaired T Test P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH</td>
<td>1.6461 ± 0.08099</td>
<td>2.8172 ± 1.6795</td>
<td>p=0.001</td>
</tr>
<tr>
<td>FT3</td>
<td>2.5382 ± 0.4521</td>
<td>2.0304 ± 0.5356</td>
<td>p=0.001</td>
</tr>
<tr>
<td>FT4</td>
<td>1.1518 ± 0.201822</td>
<td>1.0354 ± 0.2104</td>
<td>p=0.008</td>
</tr>
</tbody>
</table>

*Table 4. Correlation of Thyroid Dysfunction between Group A and Group B*
Thyroid Dysfunction (Mean ± SD) | Group A (n=50) | Group C (n=50) | Unpaired T Test P value
--- | --- | --- | ---
TSH | 1.6461 ± 0.8099 | 3.7062 ± 1.9796 | p=0.001
FT3 | 2.5302 ± 0.4521 | 1.9006 ± 0.4930 | p=0.001
FT4 | 1.1518 ± 0.20182 | 0.8801 ± 0.1749 | p=0.001

Table 5. Correlation of Thyroid Dysfunction between Group A and Group C

Figure 1 shows that all of the 5 patients who had overt hypothyroidism were in WHO clinical stage IV and majority of patients with thyroid function abnormalities belonged to WHO stage III and IV.

Figure 2. Distribution of Thyroid Dysfunction according to WHO Clinical Stage

All the 5 patients who had overt hypothyroidism had HIV duration > 1 year, while 10/14 (71%) patients had subclinical hypothyroidism had HIV duration > 1 year, 3/4 (75%) patients with isolated low FT4 had HIV duration > 1 year and 23/39 (59%) patients with sick euthyroid syndrome had HIV duration > 1 year (Figure 2).

Figure 2. Distribution of Thyroid Dysfunction according to duration of HIV

Above observation shows that thyroid disorders in HIV patients become more common as duration of disease increases. On correlating the level of FT3, FT4 and TSH with the WHO stage shows that the level of FT3 and FT4 goes on decreasing from stage I to stage IV (p value= 0.000) and the level of TSH goes on increasing from stage I to stage IV (p value= 0.000). Thus, as the clinical severity of HIV infection increases, the level of FT3 and FT4 decreases and TSH increases.

On correlating FT3, FT4 and TSH level with CD4 count, a positive correlation between FT3 level and CD4 count is found (Pearson correlation coefficient= 0.4249, p value= 0.000), a positive correlation between FT4 level and CD4 count (Pearson correlation coefficient= 0.2972, p value= 0.0001) is also found, while a negative correlation between S.TSH level and CD4 count (Pearson correlation coefficient= -0.4741, p value= 0.000) is also established. Above results show that as the CD4 count decreases in HIV positive patients the FT3 and FT4 level also decreases, while S. TSH level increases.

On correlating thyroid function abnormalities in patients on HAART and patients not on HAART a significant difference (p value= 0.001) is found in mean FT3, FT4 and TSH level between the two groups, which shows that thyroid function abnormalities are more prevalent in patients on HAART (Table 6).

Table 6. Correlation between Thyroid Dysfunction according to HAART

<table>
<thead>
<tr>
<th>Study Parameter</th>
<th>Study Group</th>
<th>Unpaired T-test P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FT3</td>
<td>On HAART (Mean ± SD)</td>
<td>1.96 ± 0.51</td>
</tr>
<tr>
<td></td>
<td>Not on HAART (Mean ± SD)</td>
<td>2.55 ± 0.44</td>
</tr>
<tr>
<td>FT4</td>
<td>On HAART (Mean ± SD)</td>
<td>0.95 ± 0.21</td>
</tr>
<tr>
<td></td>
<td>Not on HAART (Mean ± SD)</td>
<td>1.16 ± 0.20</td>
</tr>
<tr>
<td>TSH</td>
<td>On HAART (Mean ± SD)</td>
<td>3.2894 ± 1.86169</td>
</tr>
<tr>
<td></td>
<td>Not on HAART (Mean ± SD)</td>
<td>1.5902 ± 0.7763</td>
</tr>
</tbody>
</table>

DISCUSSION

The present study enumerates the prevalence of various thyroid function disorders in HIV positive patients and their association with various factors like CD4 count, WHO clinical stage, duration of HIV and HAART. In the present study, the prevalence of overt hypothyroidism was 3.33%, subclinical hypothyroidism was 9.33%, isolated low FT4 in 2.60% patients, while sick euthyroid syndrome was found in 26% patients.

Some other studies such as a study Varanasi,⁷ reported 30% prevalence of subclinical hypothyroidism and 10.66% prevalence of overt hypothyroidism. In this study, patients having acute illness which can alter the thyroid function were also included. The difference in results may also be due to ethnic differences and differences in the sample size. None of the patients were found to have hyperthyroidism in the present study. Similarly, earlier studies from India and western countries also did not report hyperthyroidism in any of the patients. We also noted a positive correlation between FT3, FT4 level and the CD4 count, while a negative correlation was noted between TSH and CD4 count. A study done by Mala V Kaneria etal⁸ reported a similar correlation.

The present study also shows that as the HIV patients deteriorate clinically as reflected by WHO clinical staging, the prevalence of thyroid function abnormalities increases. Earlier studies also reported similar results and thyroid function abnormalities were more common in patients receiving HAART than patients not receiving HAART. This may be due to the direct effect of antiretroviral drugs on thyroid metabolism.

The role of HAART was also confirmed by a recent report that interruption of HAART was associated with a normalisation of thyroid function test.⁹ Immune reconstitution autoimmune thyroid disease (AITD) (Grave’s disease, thyrotoxicosis and hypothyroidism) was found to be...
3% for women and 0.2% for men. The median duration of immune reconstitution was 17 months.10-12

Patients with lower CD4 count at baseline who experienced greater increments in the CD4 counts following HAART were more likely to develop AITD. But none of the patients in the present study was found to have immune reconstitution syndrome. We also found that thyroid function abnormalities become more prevalent, as duration of disease increases. This may be due to increasing incidence of opportunistic infections and decreasing CD4 count, as the duration of the infection increases.

Certain Limitations of our Study were:

1. As study design was a cross-sectional, we could not derive pathogenesis of thyroid dysfunction.
2. As this study was conducted in a tertiary care hospital, the study group does not show the population characteristics and the patient’s study could not be equally distributed for HIV associated conditions like stage of infection, CD4 count, HAART etc.
3. TFT was measured at one point in time, limiting the robustness of the relationship being considered between the variable and the thyroid function tests.

Hence, studies with larger sample size from general population with longitudinal follow-up of the patients are needed to confirm the results of the present study.

CONCLUSION
Abnormal thyroid function tests are common in HIV infected patients. Sick euthyroid syndrome, subclinical hypothyroidism and overt hypothyroidism are most common thyroid function disorders in HIV positive patients and these disorders are more prevalent in patients who have more severe disease and are on antiretroviral therapy.

Thus, patients having HIV duration > 1 year, CD4 count < 350/mm³ in WHO clinical stage III and IV and patients on HAART may require regular monitoring of thyroid function tests. Currently, there is insufficient evidence in favour of screening of thyroid abnormalities in asymptomatic HIV infected patients. Larger studies are needed to examine the epidemiology and health consequences of thyroid dysfunction in HIV patients and to better inform screening and treatment guidelines.

REFERENCES